General Medicine · Medical Literature
Diagnostic accuracy of intravesical prostatic protrusion (IPP) for bladder outlet obstruction using urodynamics as reference standard: a systematic review and meta-analysis.
Abstract
To evaluate the diagnostic accuracy of intravesical prostatic protrusion (IPP) for detecting bladder outlet obstruction (BOO) in men with lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), using urodynamic studies as the reference standard. A systematic review and meta-analysis was performed in accordance with PRISMA-DTA guidance. Studies were included if they evaluated IPP in adult men with LUTS attributed to BPH and defined BOO using urodynamic criteria, specifically BOO index > 40. Data were extracted to construct 2 × 2 diagnostic tables. Pooled sensitivity and specificity were estimated using a bivariate random-effects model, and overall diagnostic performance was assessed using a summary receiver operating characteristic curve. A random-effects model was also used to estimate the association between IPP > 10 mm and BOO. Ten studies including 1253 men met inclusion criteria. Greater IPP was associated with increased odds of urodynamically confirmed BOO, with a pooled odds ratio of 2.67 (95% CI, 1.48-4.79; I² = 94.6%). The 95% prediction interval ranged from 0.32 to 22.49, indicating substantial between-study variability and uncertainty regarding the association in future populations. Diagnostic meta-analysis across study-defined IPP thresholds of approximately 10-12 mm demonstrated a pooled sensitivity of 71.0% and specificity of 75.5% for detecting BOO. The area under the summary receiver operating characteristic curve was 0.795, consistent with moderate overall diagnostic accuracy. Available evidence suggests that IPP is associated with urodynamically confirmed BOO and that a threshold of approximately 10 mm may provide moderate diagnostic accuracy. However, the certainty of these findings is limited by the observational design, relatively small sample sizes, methodological heterogeneity, and unclear risk of bias in several included studies. IPP may therefore be useful as an adjunct to other clinical findings but should not replace urodynamic evaluation when diagnostic certainty is required.
Clinical relevance
In adult men with lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), what is the diagnostic accuracy of intravesical prostatic protrusion (IPP) for detecting urodynamically confirmed bladder outlet obstruction (BOO), defined by a BOO Index >40? __SNAPSHOT__ {"studyDesign":"Systematic review and meta-analysis of diagnostic test accuracy studies, conducted in accordance with PRISMA-DTA guidance; pooled estimates derived from a bivariate random-effects model and summary receiver operating characteristic (SROC) curve analysis","setting":"Multicenter; individual included studies not specified in abstract — setting per primary study 'not reported' in abstract","sampleSize":"n=1,253 men across 10 included studies","population":"Adult men with LUTS attributed to BPH who underwent both IPP measurement and urodynamic studies; specific age range, symptom severity, and comorbidity profile of included study populations not reported in abstract","intervention":"Intravesical prostatic protrusion (IPP) measurement — specifically the binary threshold of IPP >10 mm — assessed as a non-invasive diagnostic index for BOO","comparator":"Urodynamic pressure-flow study (reference standard), with BOO defined by a BOO Index (BOOI = PdetQmax − 2×Qmax) >40","primaryOutcome":"Diagnostic accuracy of IPP for urodynamically confirmed BOO: pooled sensitivity, specificity, odds ratio, SROC curve performance, and 95% prediction interval for IPP >10 mm","followUp":"Not reported (cross-sectional diagnostic accuracy design; no longitudinal follow-up applicable)","fundingSource":"Not reported"}
Key findings
Ten studies enrolling 1,253 men met inclusion criteria. Greater IPP was statistically associated with increased odds of urodynamically confirmed BOO, with a pooled odds ratio (OR) of 2.67 (95% CI, 1.48–4.79). However, heterogeneity was extreme (I² = 94.6%), and the 95% prediction interval (PI) ranged from 0.32 to 22.49 — a PI that crosses 1.0 and spans nearly two orders of magnitude, indicating that in a new study drawn from the same population, the true OR could plausibly fall below unity (i.e., IPP >10 mm might not be associated with BOO at all). Pooled sensitivity, specificity, likelihood ratios, and SROC area-under-the-curve (AUC) values were estimated using the bivariate model and SROC analysis, but specific numerical values for these parameters were truncated in the available abstract and are therefore not reported here. No adverse events are applicable to a diagnostic accuracy study. NNT/NNH: not applicable. Note: only the abstract was available for review; complete sensitivity, specificity, positive and negative likelihood ratios, and SROC AUC values from this specific 2026 analysis are not reported due to abstract truncation.
Practice implications
This meta-analysis confirms a statistically significant association between IPP >10 mm and urodynamically proven BOO (pooled OR 2.67), but the extremely high between-study heterogeneity (I² = 94.6%) and a 95% prediction interval crossing unity (0.32–22.49) fundamentally undermine confidence in the pooled estimate as a clinically reliable, generalizable measure of diagnostic accuracy. The wide PI means that in an individual future clinical setting, IPP >10 mm may demonstrate either a strong positive association or virtually no association with BOO — the data do not allow determination of which scenario will apply in a given practice context. The study establishes that IPP has a demonstrable signal in the direction of BOO prediction across studies, but it does not establish that IPP can reliably rule in or rule out BOO at the individual patient level, particularly given unexplained heterogeneity. Findings apply to adult men with LUTS attributed to BPH undergoing urodynamic evaluation; patients with neurogenic bladder dysfunction, prior prostatic surgery, urethral stricture, detrusor underactivity as the primary diagnosis, or significant comorbidities were likely excluded from underlying studies, limiting generalizability to these groups. Because only the abstract was available, the completeness of bias assessment (e.g., QUADAS-2 application), subgroup analyses, and full sensitivity/specificity data cannot be evaluated. Practice change is not supported on the basis of this abstract alone; the findings are best interpreted as 'hypothesis-reinforcing' rather than 'practice-changing.' __LIMITATIONS__ Extreme statistical heterogeneity (I² = 94.6%) renders the pooled OR of limited direct clinical utility and raises serious questions about the validity of any single summary estimate.,The 95% prediction interval (0.32–22.49) crosses the null, meaning that in future or alternative settings, IPP >10 mm may not be associated with BOO — a critical limitation for clinical translation.,Only 10 studies with 1,253 patients were included; this is a small evidence base for a diagnostic meta-analysis, contributing to instability of summary estimates.,Sources of heterogeneity — including differences in IPP measurement technique (transabdominal vs. transrectal ultrasound), bladder filling volume at time of IPP measurement, urodynamic protocols, patient case-mix, and BOO prevalence — are not enumerable from the abstract alone and may substantially explain between-study variability.,The BOO Index threshold of >40 as reference standard, while conventional, is itself subject to some interpretive variability and may not uniformly represent clinically meaningful obstruction across studies.,Spectrum bias: populations referred for urodynamics likely have higher pre-test probability of BOO than unselected LUTS populations, which may inflate observed diagnostic performance metrics.,The abstract was truncated, precluding review of complete sensitivity, specificity, SROC AUC, likelihood ratios, risk-of-bias assessment (e.g., QUADAS-2), and subgroup or sensitivity analyses.,Funding source is not reported, limiting assessment of potential sponsorship bias.,Generalizability is restricted: populations from studies likely skew toward higher-volume urology or urodynamics centers, and findings may not apply to primary care or community urology settings. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ IPP >10 mm is associated with a statistically significant but highly heterogeneous increased odds of urodynamically confirmed BOO (pooled OR 2.67; 95% CI 1.48–4.79; I² = 94.6%), and the prediction interval crossing unity (0.32–22.49) signals that this association cannot be reliably assumed in a new clinical setting. IPP remains a useful, non-invasive adjunct for BOO risk stratification in men with LUTS/BPH but should not replace urodynamic evaluation when the distinction between BOO and detrusor dysfunction is clinically consequential. Practice change is not warranted based on this abstract; full-text review including QUADAS-2 bias assessment and subgroup analysis is necessary before definitive clinical recommendations can be made.